Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brain Imaging of DSP-2342
NCT07850102Phase 2Not yet recruiting
- Sponsor
- Johns Hopkins University
- Start
- Jan 2027
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of DSP-2342 in schizophrenia, sponsored by Johns Hopkins University. Primary endpoint: Glutamate levels at Day 1. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
DSP-2342
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT07850102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07850102.